# Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

> **NCT03557918** · PHASE2 · COMPLETED · sponsor: **Matthew Galsky** · enrollment: 26 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03557918
- **Lead sponsor:** Matthew Galsky
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-12
- **Primary completion:** 2021-12-06
- **Final completion:** 2023-06-07
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03557918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03557918, "Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03557918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*